BFRI Stock Overview
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biofrontera Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.84 |
| 52 Week High | US$5.28 |
| 52 Week Low | US$0.61 |
| Beta | 0.51 |
| 11 Month Change | -34.38% |
| 3 Month Change | -17.88% |
| 1 Year Change | -78.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.05% |
Recent News & Updates
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story
Sep 28
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce
Aug 09Recent updates
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story
Sep 28Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce
Aug 09Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper
May 24Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%
Dec 30The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%
Nov 13Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?
Oct 18Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours
Oct 05Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation
Sep 06Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Aug 12Biofrontera announces 2Q prelim product revenues
Jul 12Shareholder Returns
| BFRI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.3% | 0.3% |
| 1Y | -78.2% | 23.6% | 38.3% |
Return vs Industry: BFRI underperformed the US Pharmaceuticals industry which returned 23.6% over the past year.
Return vs Market: BFRI underperformed the US Market which returned 38.3% over the past year.
Price Volatility
| BFRI volatility | |
|---|---|
| BFRI Average Weekly Movement | 15.8% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BFRI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BFRI's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 84 | Hermann Luebbert | www.biofrontera-us.com |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Biofrontera Inc. Fundamentals Summary
| BFRI fundamental statistics | |
|---|---|
| Market cap | US$4.66m |
| Earnings (TTM) | -US$13.51m |
| Revenue (TTM) | US$35.24m |
0.1x
P/S Ratio-0.3x
P/E RatioIs BFRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BFRI income statement (TTM) | |
|---|---|
| Revenue | US$35.24m |
| Cost of Revenue | US$18.42m |
| Gross Profit | US$16.82m |
| Other Expenses | US$30.33m |
| Earnings | -US$13.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 47.74% |
| Net Profit Margin | -38.34% |
| Debt/Equity Ratio | 2.7% |
How did BFRI perform over the long term?
See historical performance and comparison